Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
Rank in Stocks #12094
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Share Price
$2.34
Last synced: 2026-08-28
Market Cap
$621.44M
Change (1 day)
-1.06%
Change (1 year)
55.67%
Country
GB
Trade Autolus Therapeutics plc (AUTL)

Category

Stock price history for Autolus Therapeutics plc (AUTL)
Highest end of day price: $2.28 on 2026-08-01

Lowest end of day price: $26.43 on 2018-06-01
Stock price history of Autolus Therapeutics plc from 2018 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.13 -12.98%
AU
$138.18 473.58%
US
$759.27 7.20%
CH